The clinical information you need, at your fingertips.

RNA-targeting treatment missed its primary endpoint, but secondary signals may support further development. . .

Cohort study found early insulin treatment was twice as common, reinforcing the need for sustained follow-up after pregnancy. . .

Positive phase 3 results may bring targeted immunotherapy into care before disease progression, moving tarlatamab from the relapse setting into first-line maintenance. . .

New guidance highlights fertility counseling, hormone management, contraception, and anatomy-based screening for transgender and gender-diverse patients. . .

First-of-its-kind approval uses a blood-based test to guide an early treatment switch in advanced HR-positive, HER2-negative breast cancer. . .

Real-world data suggest sustained low-dose semaglutide and tirzepatide may still produce modest weight loss, but questions remain about benefits and tolerability. . .